| scholarly article | Q13442814 |
| P50 | author | Takashi Sato | Q63545091 |
| P2093 | author name string | Takeshi Kaneko | |
| Yoshiaki Ishigatsubo | |||
| Dennis M Klinman | |||
| Takeshi Shimosato | |||
| Ryohei Takahashi | |||
| P2860 | cites work | Suppressive oligodeoxynucleotides inhibit silica-induced pulmonary inflammation. | Q39980540 |
| Adenovirus expressing p27(Kip1) induces growth arrest of lung cancer cell lines and suppresses the growth of established lung cancer xenografts | Q45874114 | ||
| Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials | Q46944826 | ||
| Suppressive oligonucleotides protect against collagen-induced arthritis in mice | Q47596728 | ||
| Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis | Q56897921 | ||
| Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides | Q56897952 | ||
| Platination of A GG Site on Single-Stranded and Double-Stranded forms of A 14-Base Oligonucleotide with Diaqua Cisplatin followed by NMR and HPLC. Influence of the Platinum Ligands and Base Sequence on 5'-G Versus 3'-G Platination Selectivity | Q64449181 | ||
| The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element | Q69535058 | ||
| Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells | Q71840966 | ||
| Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design | Q72732581 | ||
| DNA interactions of bifunctional dinuclear platinum(II) antitumor agents | Q73480144 | ||
| Prognostic value of integrin beta1-ILK-pAkt signaling pathway in non-small cell lung cancer | Q80177144 | ||
| Global cancer statistics | Q22241238 | ||
| Inflammation and cancer | Q24649640 | ||
| The retinoblastoma protein and cell cycle control | Q27860722 | ||
| CDK inhibitors: positive and negative regulators of G1-phase progression | Q27860983 | ||
| Inflammation and cancer: back to Virchow? | Q28036756 | ||
| Integrin signaling | Q28142010 | ||
| 5-Fluorouracil: mechanisms of action and clinical strategies | Q28201937 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer | Q28285050 | ||
| p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 | Q28505037 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer | Q33331108 | ||
| Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential | Q33924555 | ||
| Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. | Q33939756 | ||
| Mechanism of action of camptothecin | Q34149055 | ||
| Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil | Q34935734 | ||
| Effect of suppressive oligodeoxynucleotides on the development of inflammation-induced papillomas | Q34939860 | ||
| Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells | Q35749321 | ||
| P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 | Q36621938 | ||
| ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. | Q36694670 | ||
| Targeting the RAF-MEK-ERK pathway in cancer therapy | Q37393116 | ||
| Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock | Q38328352 | ||
| Signaling pathway requirements for induction of senescence by telomere homolog oligonucleotides | Q38334543 | ||
| Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma- and IL-12-mediated signaling. | Q38335694 | ||
| Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation | Q38352355 | ||
| Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. | Q39451375 | ||
| Telomeric plasmid induces human cancer cell dysfunction depending on ATM activity | Q39695060 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 429-436 | |
| P577 | publication date | 2012-12-28 | |
| P1433 | published in | International Journal of Oncology | Q6051527 |
| P1476 | title | Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells | |
| P478 | volume | 42 |
Search more.